Global Hemophilia B Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

• In February 2023, Hemgenix, a novel gene therapy, received approval from the European Commission for the treatment of hemophilia B.

• In April 2024, Pfizer received approval for BEQVEZ, its gene therapy designed to treat hemophilia B. BEQVEZ offers a new treatment approach by addressing the genetic root cause of the disease, potentially reducing the need for frequent injections and improving quality of life for patients with hemophilia B.

The Global Hemophilia B Market is segmented by Drugs into several categories, including Plasma-Derived Coagulation Factor Concentrate, Recombinant Coagulation Factor Concentrates, Desmopressin, and Others. Plasma-derived coagulation factor concentrates are traditionally used for replacing the deficient clotting factor in hemophilia B patients. These concentrates are derived from human plasma and are commonly used in the treatment of bleeding episodes. Recombinant coagulation factor concentrates have become increasingly popular due to their lower risk of viral transmission, as they are produced through genetic engineering. Desmopressin is used to treat mild cases of hemophilia B, helping to stimulate the release of von Willebrand factor and factor VIII in the body, improving clotting. The Others category includes emerging therapies and gene therapies, which are showing potential for long-term treatment solutions.

The market is also segmented by Treatment into On-demand and Prophylaxis. On-demand treatment involves administering factor concentrates during or after a bleeding episode to stop or prevent bleeding, whereas Prophylaxis involves regular administration of factor concentrates to prevent bleeding episodes before they occur, thereby reducing long-term joint damage and improving quality of life. In terms of Route of Administration, the market includes Oral and Injectable therapies. While injectable therapies remain the standard for hemophilia B treatment, there is ongoing research into oral treatments to provide more convenient and non-invasive alternatives. End Users include Hospitals, Homecare, Specialty Clinics, and Others. Hospitals and specialty clinics provide specialized care, while Homecare solutions are becoming more popular, allowing patients to receive treatment in the comfort of their homes. The Distribution Channel is segmented into Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy, reflecting the various ways in which hemophilia B treatments are distributed to patients, with online pharmacies growing in popularity due to convenience.

Global Hemophilia B Segment Analysis

In this report, the global hemophilia b market has been segmented by Drugs, Treatment, Route Of Administration, End User, and Geography.

Global Hemophilia B Market, Segmentation by Drugs

The Global Hemophilia B Market has been segmented by Drugs into Plasma Derived Coagulation Factor Concentrate, Recombinant Coagulation Factor Concentrates, Desmopressin, and Others.

Plasma-Derived Coagulation Factor Concentrates are traditionally used for hemophilia B treatment. These concentrates are derived from human plasma and contain clotting factor IX, which is essential for blood clotting. Despite the risk of viral transmission, these products are still widely used due to their effectiveness in treating bleeding episodes. Recombinant Coagulation Factor Concentrates have gained popularity as a safer alternative. Produced through genetic engineering, recombinant factor IX concentrates are free from the risk of viral contamination, offering a more secure option for long-term treatment and prophylaxis. They are considered the gold standard for treating hemophilia B, providing consistent quality and safety.

Desmopressin, a synthetic hormone, is used in mild cases of hemophilia B to stimulate the release of factor VIII and von Willebrand factor, improving clotting. It can be an alternative in cases where factor IX therapy is not required. The Others category includes emerging treatments such as gene therapies and non-factor replacement therapies, which aim to provide more durable solutions for hemophilia B management. Gene therapy, in particular, has shown promise in offering long-term treatment by delivering a functional copy of the defective gene, potentially reducing the need for regular factor IX infusions. This evolving class of treatments holds the potential to transform the market by offering more permanent solutions for patients with hemophilia B.

Global Hemophilia B Market, Segmentation by Treatment

The Global Hemophilia B Market has been segmented by Treatment into On-demand and Prophylaxis

On-demand treatment involves administering factor IX concentrates or other therapies when a bleeding episode occurs. The goal is to stop or prevent bleeding during or after an incident, allowing the patient to manage acute bleeding events effectively. This treatment is typically used for patients who experience infrequent or mild bleeding episodes and may not need continuous care. On-demand treatment is more reactive, focusing on providing immediate relief and controlling the bleeding until the patient recovers or the bleeding resolves.

In contrast, Prophylaxis involves the regular, scheduled administration of factor IX concentrates to prevent bleeding episodes from occurring in the first place. This proactive approach is often recommended for patients who experience frequent or severe bleeding episodes, as it helps to maintain an adequate level of clotting factor in the blood at all times, reducing the risk of bleeding and preventing long-term joint damage. Prophylactic treatment is widely considered a standard of care, particularly for children and patients with more severe forms of hemophilia B, as it improves quality of life and prevents complications associated with repeated bleeding. This strategy has shown to significantly reduce the frequency of bleeding episodes and the long-term effects of the disease.

Global Hemophilia B Market, Segmentation by Route Of Administration

The Global Hemophilia B Market has been segmented by Route Of Administration into Oral and Injectable.

Injectable therapies remain the most common and established route for treating hemophilia B. Factor IX concentrates, which are central to hemophilia B treatment, are typically administered through intravenous (IV) injection. This method provides direct delivery of the clotting factor into the bloodstream, allowing it to act quickly and effectively to prevent or control bleeding episodes. Injectable treatments are often preferred for their efficacy and rapid onset of action, particularly in both on-demand and prophylactic treatment regimens. While injections are generally more effective for managing severe cases, they require skilled administration and regular medical supervision.

In contrast, Oral therapies are an emerging option in the market, with ongoing research aimed at developing oral formulations of factor IX or alternative treatments for hemophilia B. Oral medications would provide a more convenient and patient-friendly alternative, especially for those seeking non-invasive treatment options. However, the development of oral therapies has been challenging due to the complexities of delivering clotting factors in an oral form that is both effective and safe. If successful, oral therapies could significantly improve the convenience of treatment, especially for long-term management, but they currently remain less common compared to injectable therapies. As advancements in drug formulations continue, the adoption of oral therapies is expected to grow, offering more flexibility and improving patient adherence to treatment regimens.

Global Hemophilia B Market, Segmentation by End User

The Global Hemophilia B Market has been segmented by End User into Hospitals, Homecare, Specialty Clinics, and Others.

Hospitals remain a primary end-user for hemophilia B treatments, providing advanced medical infrastructure and specialized care for patients with severe forms of hemophilia B. Hospitals typically have the necessary equipment and skilled professionals to administer intravenous factor IX concentrates or other treatments. They are essential for managing emergency situations and complex cases, where patients may need continuous monitoring or specialized interventions during bleeding episodes or surgical procedures. Hospitals are also crucial for initial diagnosis and treatment of hemophilia B, offering comprehensive healthcare services to patients.

Homecare is an increasingly popular end-user setting, particularly with the rise of home-based treatment options. Advances in portable and user-friendly hemodialysis equipment and factor IX concentrates allow patients to manage their hemophilia B treatment in the comfort of their own homes. Homecare offers greater convenience and independence for patients, especially those requiring regular prophylactic treatments. It also reduces the need for frequent hospital visits, improving the overall quality of life for individuals with hemophilia B, especially for long-term management.

Specialty Clinics focus on providing expert care for blood disorders like hemophilia B, offering specialized services that are more personalized than hospitals. These clinics cater to patients seeking expert consultation, ongoing care, and regular monitoring of their condition. They may provide treatments such as gene therapy, homecare education, or other cutting-edge solutions for hemophilia B management. The Others category includes additional settings such as rehabilitation centers, outpatient care facilities, and mobile care units that provide alternative or supplementary care options for patients. Each of these end-users plays a significant role in the overall healthcare ecosystem for hemophilia B patients, offering different levels of care depending on the severity of the condition and patient needs.

Global Hemophilia B Market, Segmentation by Distribution Channel

The Global Hemophilia B Market has been segmented by Distribution Channel into Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.

Hospital Pharmacy remains a major distribution channel for hemophilia B treatments, especially for patients receiving care in hospitals or specialty clinics. These pharmacies provide specialized and immediate access to clotting factor concentrates, emergency medications, and other essential treatments that are required for managing bleeding episodes or routine prophylactic care. Hospital pharmacies are crucial for ensuring that patients with severe or complex cases of hemophilia B have access to the necessary medications, often under the supervision of medical professionals.

Online Pharmacy is an increasingly important distribution channel, driven by the rise of e-commerce and growing patient demand for convenience. With the ability to order medications from the comfort of their homes, patients with hemophilia B can access their prescribed treatments, including factor IX concentrates and other necessary drugs, without having to visit a pharmacy in person. Online pharmacies are particularly beneficial for patients managing their condition through homecare, offering convenience and discreet purchasing options. The increasing availability of home delivery services for chronic conditions further fuels this trend.

Retail Pharmacy also plays a significant role in the distribution of hemophilia B treatments. Retail pharmacies provide easy access to medications, such as desmopressin and other supportive therapies, for patients who may not require frequent hospital visits. Many patients, particularly those with milder forms of hemophilia B, rely on retail pharmacies for regular prescriptions, including factor IX concentrates, while maintaining their outpatient treatment regimens. Retail pharmacies are often more accessible in terms of location, and they can offer personalized counseling for patients, ensuring proper medication management and adherence. Each of these distribution channels contributes to making hemophilia B treatments more accessible to patients, improving the efficiency and convenience of healthcare delivery.

Global Hemophilia B Market, Segmentation by Geography

In this report, the Global Hemophilia B Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Global Hemophilia B Market Share (%), by Geographical Region, 2024

The global market for Hemophilia B, a hereditary bleeding disorder caused by a lack of clotting factor IX, exhibits geographical variations in terms of prevalence, treatment accessibility, and healthcare infrastructure. In North America, the market is characterized by a well-established healthcare system and high awareness about the condition among both patients and healthcare providers. This region often witnesses early adoption of novel therapies and is home to several prominent pharmaceutical companies conducting research and development in the field of hemophilia B treatment.

Across Europe, the market dynamics for hemophilia B are influenced by a mix of factors including government healthcare policies, reimbursement mechanisms, and prevalence rates varying between countries. While some European nations boast advanced treatment facilities and comprehensive care programs for hemophilia patients, others face challenges related to access to specialized care and affordability of expensive therapies.

In the Asia Pacific region, the hemophilia B market is undergoing significant growth fueled by improving healthcare infrastructure, rising awareness about bleeding disorders, and increasing investments by pharmaceutical companies. However, disparities in access to treatment and diagnostic facilities exist within the region, with urban areas often having better healthcare resources compared to rural or remote areas. Efforts are underway to address these disparities through initiatives aimed at improving access to diagnosis, treatment, and patient support programs.

This report provides an in depth analysis of various factors that impact the dynamics of Global Hemophilia B Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Key players in Global Hemophilia B Market include:

• Baxter
• Grifols
• Novo Nordisk
• Pfizer

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis